{"id":526489,"date":"2021-08-11T07:08:05","date_gmt":"2021-08-11T11:08:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/"},"modified":"2021-08-11T07:08:05","modified_gmt":"2021-08-11T11:08:05","slug":"virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/","title":{"rendered":"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference"},"content":{"rendered":"

<\/p>\n

Virios Therapeutics to Present at the SNN Network Summer Virtual Conference<\/b><\/p>\n

ATLANTA–(BUSINESS WIRE<\/a>)–Virios Therapeutics, Inc.<\/a> (Nasdaq: VIRI<\/b>), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the SNN Network Summer Virtual Conference<\/a> on August 19, 2021 at 9:00 a.m. ET.\n<\/p>\n

\nThe presentation will focus on the role of activated viruses triggering a wide range of conditions, including fibromyalgia (\u201cFM\u201d), irritable bowel syndrome and fatigue-related disorders, and progress in its currently enrolling Phase 2b FM clinical trial.\n<\/p>\n

\nManagement will be available for one-on-one meetings to be held throughout the conference.\n<\/p>\n

\nThe live and archived replay of the presentation may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations<\/a>.\n<\/p>\n

About Virios Therapeutics <\/b><\/p>\n

\nVirios Therapeutics (Nasdaq: VIRI<\/b>) is a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (\u201cFM\u201d). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (\u201cHSV-1\u201d) have been postulated as a potential root cause triggering and\/or sustaining chronic illnesses such as FM, irritable bowel disease (\u201cIBS\u201d), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (\u201cIMC-1\u201d) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.\n<\/p>\n

\nEvidence of IMC-1\u2019s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial. These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (\u201cFORTRESS\u201d) designed to set the stage for registrational studies. The company is led by an executive team highly experienced in the successful development and commercialization of novel therapies. For more information, please visit www.virios.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nStatements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d “will\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics\u2019 current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of the Phase 2b trial. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update such information except as required under applicable law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210811005050\/en\/<\/a><\/span><\/p>\n

\nDave Gentry
\n
1-800-733-2447
\n
+1-407-491-4498
\n
dave@redchip.com<\/a><\/p>\n

\nor\n<\/p>\n

ir@virios.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Georgia<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Other Health Health General Health Women Other Science Research Infectious Diseases Consumer Science Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Virios Therapeutics to Present at the SNN Network Summer Virtual Conference ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the SNN Network Summer Virtual Conference on August 19, 2021 at 9:00 a.m. ET. The presentation will focus on the role of activated viruses triggering a wide range of conditions, including fibromyalgia (\u201cFM\u201d), irritable bowel syndrome and fatigue-related disorders, and progress in its currently enrolling Phase 2b FM clinical trial. Management will be available for one-on-one meetings to be held throughout the conference. The live and archived replay of the presentation may … <\/p>\n

Continue reading “Virios Therapeutics to Present at the SNN Network Summer Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-526489","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVirios Therapeutics to Present at the SNN Network Summer Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the SNN Network Summer Virtual Conference on August 19, 2021 at 9:00 a.m. ET. The presentation will focus on the role of activated viruses triggering a wide range of conditions, including fibromyalgia (\u201cFM\u201d), irritable bowel syndrome and fatigue-related disorders, and progress in its currently enrolling Phase 2b FM clinical trial. Management will be available for one-on-one meetings to be held throughout the conference. The live and archived replay of the presentation may … Continue reading "Virios Therapeutics to Present at the SNN Network Summer Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-11T11:08:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference\",\"datePublished\":\"2021-08-11T11:08:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/\"},\"wordCount\":620,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/\",\"name\":\"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-08-11T11:08:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference - Market Newsdesk","og_description":"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the SNN Network Summer Virtual Conference on August 19, 2021 at 9:00 a.m. ET. The presentation will focus on the role of activated viruses triggering a wide range of conditions, including fibromyalgia (\u201cFM\u201d), irritable bowel syndrome and fatigue-related disorders, and progress in its currently enrolling Phase 2b FM clinical trial. Management will be available for one-on-one meetings to be held throughout the conference. The live and archived replay of the presentation may … Continue reading \"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-11T11:08:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference","datePublished":"2021-08-11T11:08:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/"},"wordCount":620,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/","name":"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-08-11T11:08:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210811005050r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-present-at-the-snn-network-summer-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Virios Therapeutics to Present at the SNN Network Summer Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=526489"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526489\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=526489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=526489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=526489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}